You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAcetyldigitoxin
Accession NumberDB00511  (APRD01334)
TypeSmall Molecule
GroupsApproved
DescriptionCardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.
Structure
Thumb
Synonyms
Acetildigitoxina
Acetyl-digitoxin-alpha
Acetyldiginatin
Acetyldigitoxinum
Acetylgitaloxin
Acetylgitoxin
alpha-Acetyldigitoxin
alpha-Acetylgitaloxin
alpha-Monoacetyldigitoxin
Desglucolanatoside A
Digitoxin 3'''-acetate
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0ZV4Q4L2FU
CAS number1111-39-3
WeightAverage: 806.9757
Monoisotopic: 806.44525682
Chemical FormulaC43H66O14
InChI KeyHPMZBILYSWLILX-UMDUKNJSSA-N
InChI
InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1
IUPAC Name
(2R,3R,4S,6S)-3-hydroxy-6-{[(2R,3S,4S,6S)-4-hydroxy-6-{[(2R,3S,4S,6R)-4-hydroxy-6-{[(1S,2S,5S,7R,10R,11S,14R,15R)-11-hydroxy-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-4-yl acetate
SMILES
[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[[email protected]](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[[email protected]]1C[[email protected]](O)[[email protected]](O[[email protected]]2C[[email protected]](O)[[email protected]](O[[email protected]]3C[[email protected]](OC(C)=O)[[email protected]](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1
Pharmacology
IndicationUsed for fast digitalization in congestive heart failure.
Structured Indications Not Available
PharmacodynamicsThe main pharmacological effects of acetyldigitoxin are on the heart. Extracardiac effects are responsible for many of the adverse effects. Its main cardiac effects are 1) a decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter, and 2) an increase of force of contraction via inhibition of the Na+/K+ ATPase pump.
Mechanism of actionAcetyldigitoxin binds to a site on the extracellular aspect of the α-subunit of the Na+/K+ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na+/K+ pump leads to increased Na+ levels, which in turn slows down the extrusion of Ca2+ via the Na+/Ca2+ exchange pump. Increased amounts of Ca2+ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by acetyldigitoxin. This is a different mechanism from that of catecholamines. Acetyldigitoxin also increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium/potassium-transporting ATPase subunit alpha-1Proteinyes
inhibitor
HumanP05023 details
Related Articles
AbsorptionBioavailability is 60 to 80% following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityToxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD50 = 7.8 mg/kg (orally in mice).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideAcetyldigitoxin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-MethoxyestradiolAcetyldigitoxin may decrease the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideAcetyldigitoxin may decrease the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,4-Dihydroxybenzoic AcidAcetyldigitoxin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
5,10-Dideazatetrahydrofolic AcidAcetyldigitoxin may decrease the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.Experimental
7-HydroxystaurosporineAcetyldigitoxin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental
8-azaguanineAcetyldigitoxin may decrease the cardiotoxic activities of 8-azaguanine.Experimental
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineAcetyldigitoxin may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbirateroneAcetyldigitoxin may decrease the cardiotoxic activities of Abiraterone.Approved
ABT-263Acetyldigitoxin may decrease the cardiotoxic activities of ABT-263.Investigational
AcebutololAcebutolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AclarubicinAcetyldigitoxin may decrease the cardiotoxic activities of Aclarubicin.Investigational
ActeosideAcetyldigitoxin may decrease the cardiotoxic activities of Acteoside.Investigational
AfatinibAcetyldigitoxin may decrease the cardiotoxic activities of Afatinib.Approved
AfimoxifeneAcetyldigitoxin may decrease the cardiotoxic activities of Afimoxifene.Investigational
AfliberceptAcetyldigitoxin may decrease the cardiotoxic activities of Aflibercept.Approved
AlatrofloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleAcetyldigitoxin may decrease the cardiotoxic activities of Albendazole.Approved, Vet Approved
AldesleukinAcetyldigitoxin may decrease the cardiotoxic activities of Aldesleukin.Approved
AlemtuzumabAcetyldigitoxin may decrease the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlfacalcidolAlfacalcidol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved, Nutraceutical
AlitretinoinAcetyldigitoxin may decrease the cardiotoxic activities of Alitretinoin.Approved, Investigational
Alpha-DifluoromethylornithineAcetyldigitoxin may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.Experimental
AlprenololAlprenolol may increase the bradycardic activities of Acetyldigitoxin.Approved, Withdrawn
AltretamineAcetyldigitoxin may decrease the cardiotoxic activities of Altretamine.Approved
Amg 386Acetyldigitoxin may decrease the cardiotoxic activities of Amg 386.Investigational
AmikacinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Amikacin.Approved, Vet Approved
AmilorideThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Amiloride.Approved
AminocamptothecinAcetyldigitoxin may decrease the cardiotoxic activities of Aminocamptothecin.Investigational
AminoglutethimideAcetyldigitoxin may decrease the cardiotoxic activities of Aminoglutethimide.Approved
Aminolevulinic acidAcetyldigitoxin may decrease the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Acetyldigitoxin can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Acetyldigitoxin can be increased when it is combined with Amodiaquine.Approved
AmonafideAcetyldigitoxin may decrease the cardiotoxic activities of Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin.Approved, Investigational
AmrubicinAcetyldigitoxin may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineAcetyldigitoxin may decrease the cardiotoxic activities of Amsacrine.Approved
AnagrelideAcetyldigitoxin may decrease the cardiotoxic activities of Anagrelide.Approved
AnastrozoleAcetyldigitoxin may decrease the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveAcetyldigitoxin may decrease the cardiotoxic activities of Anecortave.Investigational
annamycinAcetyldigitoxin may decrease the cardiotoxic activities of annamycin.Investigational
Aop200704Aop200704 may increase the bradycardic activities of Acetyldigitoxin.Investigational
AP 12009Acetyldigitoxin may decrease the cardiotoxic activities of AP 12009.Investigational
AP24534Acetyldigitoxin may decrease the cardiotoxic activities of AP24534.Investigational
ApaziquoneAcetyldigitoxin may decrease the cardiotoxic activities of Apaziquone.Investigational
ApramycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Apramycin.Experimental, Vet Approved
ArbekacinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Arbekacin.Approved
ArotinololArotinolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Arsenic trioxideAcetyldigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
ASA404Acetyldigitoxin may decrease the cardiotoxic activities of ASA404.Investigational
AsparaginaseAcetyldigitoxin may decrease the cardiotoxic activities of Asparaginase.Approved
AT-101Acetyldigitoxin may decrease the cardiotoxic activities of AT-101.Investigational
AtenololAtenolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Atracurium besylateAtracurium besylate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AxitinibAcetyldigitoxin may decrease the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineAcetyldigitoxin may decrease the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineAcetyldigitoxin may decrease the cardiotoxic activities of Azathioprine.Approved
AZD2171Acetyldigitoxin may decrease the cardiotoxic activities of AZD2171.Investigational
Azd4547Acetyldigitoxin may decrease the cardiotoxic activities of Azd4547.Investigational
Azelaic AcidAcetyldigitoxin may decrease the cardiotoxic activities of Azelaic Acid.Approved
AzithromycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Azithromycin.Approved
BalsalazideThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide.Approved, Investigational
BatimastatAcetyldigitoxin may decrease the cardiotoxic activities of Batimastat.Experimental
BefunololBefunolol may increase the bradycardic activities of Acetyldigitoxin.Experimental
BelinostatAcetyldigitoxin may decrease the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanAcetyldigitoxin may decrease the cardiotoxic activities of Belotecan.Investigational
BendamustineAcetyldigitoxin may decrease the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Acetyldigitoxin.Approved
BesifloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Besifloxacin.Approved
BetaxololBetaxolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Betulinic AcidAcetyldigitoxin may decrease the cardiotoxic activities of Betulinic Acid.Investigational
BevacizumabAcetyldigitoxin may decrease the cardiotoxic activities of Bevacizumab.Approved, Investigational
BevantololBevantolol may increase the bradycardic activities of Acetyldigitoxin.Approved
BexaroteneAcetyldigitoxin may decrease the cardiotoxic activities of Bexarotene.Approved, Investigational
Bgj398Acetyldigitoxin may decrease the cardiotoxic activities of Bgj398.Investigational
BicalutamideAcetyldigitoxin may decrease the cardiotoxic activities of Bicalutamide.Approved
BisoprololBisoprolol may increase the bradycardic activities of Acetyldigitoxin.Approved
BizelesinAcetyldigitoxin may decrease the cardiotoxic activities of Bizelesin.Investigational
BleomycinAcetyldigitoxin may decrease the cardiotoxic activities of Bleomycin.Approved
BlinatumomabAcetyldigitoxin may decrease the cardiotoxic activities of Blinatumomab.Approved
Bmn 673Acetyldigitoxin may decrease the cardiotoxic activities of Bmn 673.Investigational
BopindololBopindolol may increase the bradycardic activities of Acetyldigitoxin.Approved
BortezomibAcetyldigitoxin may decrease the cardiotoxic activities of Bortezomib.Approved, Investigational
BosutinibAcetyldigitoxin may decrease the cardiotoxic activities of Bosutinib.Approved
Brentuximab vedotinAcetyldigitoxin may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
BroxuridineAcetyldigitoxin may decrease the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Acetyldigitoxin may decrease the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Acetyldigitoxin may decrease the cardiotoxic activities of BSI-201.Investigational
BucindololBucindolol may increase the bradycardic activities of Acetyldigitoxin.Investigational
BufuralolBufuralol may increase the bradycardic activities of Acetyldigitoxin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin.Approved
BupranololBupranolol may increase the bradycardic activities of Acetyldigitoxin.Approved
BusulfanAcetyldigitoxin may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineAcetyldigitoxin may decrease the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelAcetyldigitoxin may decrease the cardiotoxic activities of Cabazitaxel.Approved
CabergolineAcetyldigitoxin may decrease the cardiotoxic activities of Cabergoline.Approved
CabozantinibAcetyldigitoxin may decrease the cardiotoxic activities of Cabozantinib.Approved
CaiAcetyldigitoxin may decrease the cardiotoxic activities of Cai.Investigational
CalcidiolCalcidiol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved, Nutraceutical
CalcipotriolAcetyldigitoxin may decrease the cardiotoxic activities of Calcipotriol.Approved
CalcitriolCalcitriol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved, Nutraceutical
CalciumCalcium may increase the arrhythmogenic activities of Acetyldigitoxin.Nutraceutical
Calcium AcetateCalcium Acetate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
Calcium carbonateCalcium carbonate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
Calcium ChlorideCalcium Chloride may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
Calcium citrateCalcium citrate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
Calcium glubionateCalcium glubionate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
Calcium GluceptateCalcium Gluceptate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
Calcium gluconateCalcium gluconate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved, Vet Approved
CamptothecinAcetyldigitoxin may decrease the cardiotoxic activities of Camptothecin.Experimental
CapecitabineAcetyldigitoxin may decrease the cardiotoxic activities of Capecitabine.Approved, Investigational
CarbimazoleThe serum concentration of Acetyldigitoxin can be increased when it is combined with Carbimazole.Approved
CarbomycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Carbomycin.Vet Approved
CarboplatinAcetyldigitoxin may decrease the cardiotoxic activities of Carboplatin.Approved
CarfilzomibAcetyldigitoxin may decrease the cardiotoxic activities of Carfilzomib.Approved
CarmofurAcetyldigitoxin may decrease the cardiotoxic activities of Carmofur.Withdrawn
CarmustineAcetyldigitoxin may decrease the cardiotoxic activities of Carmustine.Approved
CarteololCarteolol may increase the bradycardic activities of Acetyldigitoxin.Approved
CarvedilolCarvedilol may increase the bradycardic activities of Acetyldigitoxin.Approved, Investigational
CatumaxomabAcetyldigitoxin may decrease the cardiotoxic activities of Catumaxomab.Investigational
CB1954Acetyldigitoxin may decrease the cardiotoxic activities of CB1954.Experimental
CediranibAcetyldigitoxin may decrease the cardiotoxic activities of Cediranib.Investigational
CelecoxibAcetyldigitoxin may decrease the cardiotoxic activities of Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the bradycardic activities of Acetyldigitoxin.Approved, Investigational
CeritinibAcetyldigitoxin may decrease the cardiotoxic activities of Ceritinib.Approved
CetuximabAcetyldigitoxin may decrease the cardiotoxic activities of Cetuximab.Approved
ChlorambucilAcetyldigitoxin may decrease the cardiotoxic activities of Chlorambucil.Approved
ChloroquineThe serum concentration of Acetyldigitoxin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetyldigitoxin.Approved, Vet Approved
ChlorotrianiseneAcetyldigitoxin may decrease the cardiotoxic activities of Chlorotrianisene.Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acetyldigitoxin.Approved
CholecalciferolCholecalciferol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinAcetyldigitoxin may decrease the cardiotoxic activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
Cisatracurium besylateCisatracurium besylate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
CisplatinAcetyldigitoxin may decrease the cardiotoxic activities of Cisplatin.Approved
CladribineAcetyldigitoxin may decrease the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Clarithromycin.Approved
ClofarabineAcetyldigitoxin may decrease the cardiotoxic activities of Clofarabine.Approved, Investigational
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.Approved
clorarabineAcetyldigitoxin may decrease the cardiotoxic activities of clorarabine.Investigational
ColchicineAcetyldigitoxin may decrease the cardiotoxic activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CordycepinAcetyldigitoxin may decrease the cardiotoxic activities of Cordycepin.Investigational
CrenolanibAcetyldigitoxin may decrease the cardiotoxic activities of Crenolanib.Investigational
CrizotinibAcetyldigitoxin may decrease the cardiotoxic activities of Crizotinib.Approved
CurcuminAcetyldigitoxin may decrease the cardiotoxic activities of Curcumin.Investigational
CyclophosphamideAcetyldigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
Cyproterone acetateAcetyldigitoxin may decrease the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineAcetyldigitoxin may decrease the cardiotoxic activities of Cytarabine.Approved, Investigational
DabrafenibAcetyldigitoxin may decrease the cardiotoxic activities of Dabrafenib.Approved
DacarbazineAcetyldigitoxin may decrease the cardiotoxic activities of Dacarbazine.Approved, Investigational
DactinomycinAcetyldigitoxin may decrease the cardiotoxic activities of Dactinomycin.Approved
DaratumumabAcetyldigitoxin may decrease the cardiotoxic activities of Daratumumab.Approved
DasatinibAcetyldigitoxin may decrease the cardiotoxic activities of Dasatinib.Approved, Investigational
DaunorubicinAcetyldigitoxin may decrease the cardiotoxic activities of Daunorubicin.Approved
DecamethoniumDecamethonium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
DecitabineAcetyldigitoxin may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
Denileukin diftitoxAcetyldigitoxin may decrease the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DeoxyspergualinAcetyldigitoxin may decrease the cardiotoxic activities of Deoxyspergualin.Investigational
DexamethasoneAcetyldigitoxin may decrease the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneAcetyldigitoxin may decrease the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DienogestAcetyldigitoxin may decrease the cardiotoxic activities of Dienogest.Approved
DiethylstilbestrolAcetyldigitoxin may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
DihydrostreptomycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Dihydrostreptomycin.Vet Approved
DihydrotachysterolDihydrotachysterol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
DiindolylmethaneAcetyldigitoxin may decrease the cardiotoxic activities of Diindolylmethane.Investigational
DiltiazemDiltiazem may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.Approved
DinutuximabAcetyldigitoxin may decrease the cardiotoxic activities of Dinutuximab.Approved
DocetaxelAcetyldigitoxin may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
Domoic AcidDomoic Acid may increase the arrhythmogenic activities of Acetyldigitoxin.Experimental
Doxacurium chlorideDoxacurium chloride may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
DoxercalciferolDoxercalciferol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
DoxifluridineAcetyldigitoxin may decrease the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinAcetyldigitoxin may decrease the cardiotoxic activities of Doxorubicin.Approved, Investigational
EcabetAcetyldigitoxin may decrease the cardiotoxic activities of Ecabet.Approved, Investigational
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.Approved
efaproxiralAcetyldigitoxin may decrease the cardiotoxic activities of efaproxiral.Investigational
EflornithineAcetyldigitoxin may decrease the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Acetyldigitoxin may decrease the cardiotoxic activities of EG009.Investigational
ElsamitrucinAcetyldigitoxin may decrease the cardiotoxic activities of Elsamitrucin.Investigational
EndostatinAcetyldigitoxin may decrease the cardiotoxic activities of Endostatin.Investigational
EnoxacinAcetyldigitoxin may decrease the cardiotoxic activities of Enoxacin.Approved
EnrofloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatAcetyldigitoxin may decrease the cardiotoxic activities of Entinostat.Investigational
EpirubicinAcetyldigitoxin may decrease the cardiotoxic activities of Epirubicin.Approved
EplerenoneThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Eplerenone.Approved
EpofolateAcetyldigitoxin may decrease the cardiotoxic activities of Epofolate.Investigational
Epothilone BAcetyldigitoxin may decrease the cardiotoxic activities of Epothilone B.Experimental, Investigational
ErgocalciferolErgocalciferol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved, Nutraceutical
EribulinAcetyldigitoxin may decrease the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibAcetyldigitoxin may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the bradycardic activities of Acetyldigitoxin.Approved
EstramustineAcetyldigitoxin may decrease the cardiotoxic activities of Estramustine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigitoxin.Approved
EtanidazoleAcetyldigitoxin may decrease the cardiotoxic activities of Etanidazole.Investigational
Ethiodized oilAcetyldigitoxin may decrease the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateAcetyldigitoxin may decrease the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoposideAcetyldigitoxin may decrease the cardiotoxic activities of Etoposide.Approved
EverolimusAcetyldigitoxin may decrease the cardiotoxic activities of Everolimus.Approved
ExatecanAcetyldigitoxin may decrease the cardiotoxic activities of Exatecan.Investigational
ExemestaneAcetyldigitoxin may decrease the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindAcetyldigitoxin may decrease the cardiotoxic activities of exisulind.Investigational
FenretinideAcetyldigitoxin may decrease the cardiotoxic activities of Fenretinide.Investigational
FiacitabineAcetyldigitoxin may decrease the cardiotoxic activities of Fiacitabine.Investigational
FlavopiridolAcetyldigitoxin may decrease the cardiotoxic activities of Flavopiridol.Experimental, Investigational
FleroxacinAcetyldigitoxin may decrease the cardiotoxic activities of Fleroxacin.Approved
FloxuridineAcetyldigitoxin may decrease the cardiotoxic activities of Floxuridine.Approved
FludarabineAcetyldigitoxin may decrease the cardiotoxic activities of Fludarabine.Approved
FlumequineAcetyldigitoxin may decrease the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilAcetyldigitoxin may decrease the cardiotoxic activities of Fluorouracil.Approved
FlutamideAcetyldigitoxin may decrease the cardiotoxic activities of Flutamide.Approved
FormestaneAcetyldigitoxin may decrease the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinAcetyldigitoxin may decrease the cardiotoxic activities of Formycin.Experimental
FotemustineAcetyldigitoxin may decrease the cardiotoxic activities of Fotemustine.Experimental
FramycetinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Framycetin.Approved
FulvestrantAcetyldigitoxin may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinAcetyldigitoxin may decrease the cardiotoxic activities of Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigitoxin.Approved, Vet Approved
Gallamine TriethiodideGallamine Triethiodide may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
Gallium nitrateAcetyldigitoxin may decrease the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinAcetyldigitoxin may decrease the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibAcetyldigitoxin may decrease the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinAcetyldigitoxin may decrease the cardiotoxic activities of Geldanamycin.Experimental
GemcitabineAcetyldigitoxin may decrease the cardiotoxic activities of Gemcitabine.Approved
GemifloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinAcetyldigitoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GeneticinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Geneticin.Experimental
GenisteinAcetyldigitoxin may decrease the cardiotoxic activities of Genistein.Investigational
GentamicinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of Acetyldigitoxin can be decreased when it is combined with GENTAMICIN C1A.Experimental
Ginsenoside CAcetyldigitoxin may decrease the cardiotoxic activities of Ginsenoside C.Nutraceutical
GoserelinAcetyldigitoxin may decrease the cardiotoxic activities of Goserelin.Approved
GrepafloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Grepafloxacin.Withdrawn
GusperimusAcetyldigitoxin may decrease the cardiotoxic activities of Gusperimus.Investigational
HadacidinAcetyldigitoxin may decrease the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneAcetyldigitoxin may decrease the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HexestrolAcetyldigitoxin may decrease the cardiotoxic activities of Hexestrol.Withdrawn
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetyldigitoxin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin.Approved
HydroxychloroquineThe serum concentration of Acetyldigitoxin can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateAcetyldigitoxin may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaAcetyldigitoxin may decrease the cardiotoxic activities of Hydroxyurea.Approved
Hygromycin BThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Hygromycin B.Vet Approved
IbrutinibAcetyldigitoxin may decrease the cardiotoxic activities of Ibrutinib.Approved
IdarubicinAcetyldigitoxin may decrease the cardiotoxic activities of Idarubicin.Approved
IdelalisibAcetyldigitoxin may decrease the cardiotoxic activities of Idelalisib.Approved
IfosfamideAcetyldigitoxin may decrease the cardiotoxic activities of Ifosfamide.Approved
Il 4Acetyldigitoxin may decrease the cardiotoxic activities of Il 4.Investigational
ImatinibAcetyldigitoxin may decrease the cardiotoxic activities of Imatinib.Approved
ImiquimodAcetyldigitoxin may decrease the cardiotoxic activities of Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigitoxin.Approved
IndenololIndenolol may increase the bradycardic activities of Acetyldigitoxin.Withdrawn
IndirubinAcetyldigitoxin may decrease the cardiotoxic activities of Indirubin.Investigational
INNO-206The serum concentration of Acetyldigitoxin can be decreased when it is combined with INNO-206.Investigational
Interferon beta-1aAcetyldigitoxin may decrease the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
Interferon beta-1bAcetyldigitoxin may decrease the cardiotoxic activities of Interferon beta-1b.Approved
IobenguaneAcetyldigitoxin may decrease the cardiotoxic activities of Iobenguane.Approved
IpilimumabAcetyldigitoxin may decrease the cardiotoxic activities of Ipilimumab.Approved
IrinotecanAcetyldigitoxin may decrease the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenAcetyldigitoxin may decrease the cardiotoxic activities of Irofulven.Investigational
ItraconazoleThe serum concentration of Acetyldigitoxin can be increased when it is combined with Itraconazole.Approved, Investigational
IxabepiloneAcetyldigitoxin may decrease the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibAcetyldigitoxin may decrease the cardiotoxic activities of Ixazomib.Approved
JosamycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Josamycin.Approved
KanamycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Kanamycin.Approved, Vet Approved
KaolinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Kaolin.Approved
KitasamycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Kitasamycin.Experimental
KOS-1584Acetyldigitoxin may decrease the cardiotoxic activities of KOS-1584.Investigational
L-alanosineAcetyldigitoxin may decrease the cardiotoxic activities of L-alanosine.Investigational
LabetalolLabetalol may increase the bradycardic activities of Acetyldigitoxin.Approved
LanreotideAcetyldigitoxin may decrease the cardiotoxic activities of Lanreotide.Approved
LapatinibAcetyldigitoxin may decrease the cardiotoxic activities of Lapatinib.Approved, Investigational
LeflunomideAcetyldigitoxin may decrease the cardiotoxic activities of Leflunomide.Approved, Investigational
LenalidomideAcetyldigitoxin may decrease the cardiotoxic activities of Lenalidomide.Approved
LenvatinibAcetyldigitoxin may decrease the cardiotoxic activities of Lenvatinib.Approved
LetrozoleAcetyldigitoxin may decrease the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideAcetyldigitoxin may decrease the cardiotoxic activities of Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the bradycardic activities of Acetyldigitoxin.Approved
LevofloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
LiarozoleAcetyldigitoxin may decrease the cardiotoxic activities of Liarozole.Investigational
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Acetyldigitoxin.Approved
LomefloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Lomefloxacin.Approved
LomustineAcetyldigitoxin may decrease the cardiotoxic activities of Lomustine.Approved
LonidamineAcetyldigitoxin may decrease the cardiotoxic activities of Lonidamine.Approved, Investigational
Ly2801653Acetyldigitoxin may decrease the cardiotoxic activities of Ly2801653.Investigational
LycopeneAcetyldigitoxin may decrease the cardiotoxic activities of Lycopene.Approved
MafosfamideAcetyldigitoxin may decrease the cardiotoxic activities of Mafosfamide.Investigational
MasitinibAcetyldigitoxin may decrease the cardiotoxic activities of Masitinib.Vet Approved
MasoprocolAcetyldigitoxin may decrease the cardiotoxic activities of Masoprocol.Approved
MaxacalcitolAcetyldigitoxin may decrease the cardiotoxic activities of Maxacalcitol.Approved
MDX-1106Acetyldigitoxin may decrease the cardiotoxic activities of MDX-1106.Investigational
MebendazoleAcetyldigitoxin may decrease the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineAcetyldigitoxin may decrease the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneAcetyldigitoxin may decrease the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateAcetyldigitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateAcetyldigitoxin may decrease the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelphalanAcetyldigitoxin may decrease the cardiotoxic activities of Melphalan.Approved
MequinolAcetyldigitoxin may decrease the cardiotoxic activities of Mequinol.Approved
MercaptopurineAcetyldigitoxin may decrease the cardiotoxic activities of Mercaptopurine.Approved
MesalazineThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Mesalazine.Approved
MethimazoleThe serum concentration of Acetyldigitoxin can be increased when it is combined with Methimazole.Approved
MethotrexateAcetyldigitoxin may decrease the cardiotoxic activities of Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigitoxin.Approved
Methyl aminolevulinateAcetyldigitoxin may decrease the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylprednisoloneAcetyldigitoxin may decrease the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethyltestosteroneAcetyldigitoxin may decrease the cardiotoxic activities of Methyltestosterone.Approved
MetipranololMetipranolol may increase the bradycardic activities of Acetyldigitoxin.Approved
MetocurineMetocurine may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
Metocurine IodideMetocurine Iodide may increase the arrhythmogenic activities of Acetyldigitoxin.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Acetyldigitoxin.Approved
MetoprololMetoprolol may increase the bradycardic activities of Acetyldigitoxin.Approved, Investigational
MetrizamideThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Metrizamide.Approved
MGI-114Acetyldigitoxin may decrease the cardiotoxic activities of MGI-114.Investigational
MidodrineAcetyldigitoxin may increase the bradycardic activities of Midodrine.Approved
MidostaurinAcetyldigitoxin may decrease the cardiotoxic activities of Midostaurin.Investigational
MiltefosineAcetyldigitoxin may decrease the cardiotoxic activities of Miltefosine.Approved
MisonidazoleAcetyldigitoxin may decrease the cardiotoxic activities of Misonidazole.Investigational
MitoguazoneAcetyldigitoxin may decrease the cardiotoxic activities of Mitoguazone.Investigational
MitolactolAcetyldigitoxin may decrease the cardiotoxic activities of Mitolactol.Investigational
MitomycinAcetyldigitoxin may decrease the cardiotoxic activities of Mitomycin.Approved
MitotaneAcetyldigitoxin may decrease the cardiotoxic activities of Mitotane.Approved
MitoxantroneAcetyldigitoxin may decrease the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
MizoribineAcetyldigitoxin may decrease the cardiotoxic activities of Mizoribine.Investigational
MLN576Acetyldigitoxin may decrease the cardiotoxic activities of MLN576.Investigational
MolgramostimAcetyldigitoxin may decrease the cardiotoxic activities of Molgramostim.Investigational
motexafin gadoliniumAcetyldigitoxin may decrease the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolic acidAcetyldigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.Approved
NadololNadolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Nalidixic AcidAcetyldigitoxin may decrease the cardiotoxic activities of Nalidixic Acid.Approved
NamitecanAcetyldigitoxin may decrease the cardiotoxic activities of Namitecan.Investigational
NavitoclaxAcetyldigitoxin may decrease the cardiotoxic activities of Navitoclax.Investigational
NeamineThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Neamine.Experimental
NecitumumabAcetyldigitoxin may decrease the cardiotoxic activities of Necitumumab.Approved
NelarabineAcetyldigitoxin may decrease the cardiotoxic activities of Nelarabine.Approved, Investigational
NeomycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the arrhythmogenic activities of Acetyldigitoxin.Investigational
NetilmicinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Netilmicin.Approved
NiguldipineAcetyldigitoxin may decrease the cardiotoxic activities of Niguldipine.Experimental
NilotinibAcetyldigitoxin may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideAcetyldigitoxin may decrease the cardiotoxic activities of Nilutamide.Approved
NimustineAcetyldigitoxin may decrease the cardiotoxic activities of Nimustine.Investigational
NintedanibAcetyldigitoxin may decrease the cardiotoxic activities of Nintedanib.Approved
NivolumabAcetyldigitoxin may decrease the cardiotoxic activities of Nivolumab.Approved
Nk012Acetyldigitoxin may decrease the cardiotoxic activities of Nk012.Investigational
nocodazoleAcetyldigitoxin may decrease the cardiotoxic activities of nocodazole.Experimental
NolatrexedAcetyldigitoxin may decrease the cardiotoxic activities of Nolatrexed.Investigational
NorfloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabAcetyldigitoxin may decrease the cardiotoxic activities of Obinutuzumab.Approved
OctreotideAcetyldigitoxin may decrease the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabAcetyldigitoxin may decrease the cardiotoxic activities of Ofatumumab.Approved
OfloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Ofloxacin.Approved
OlaparibAcetyldigitoxin may decrease the cardiotoxic activities of Olaparib.Approved
OleandomycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Oleandomycin.Vet Approved
OlsalazineThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Olsalazine.Approved
Omacetaxine mepesuccinateAcetyldigitoxin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OprelvekinAcetyldigitoxin may decrease the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibAcetyldigitoxin may decrease the cardiotoxic activities of Osimertinib.Approved
OxaliplatinAcetyldigitoxin may decrease the cardiotoxic activities of Oxaliplatin.Approved, Investigational
OxprenololOxprenolol may increase the bradycardic activities of Acetyldigitoxin.Approved
PaclitaxelAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
PalbociclibAcetyldigitoxin may decrease the cardiotoxic activities of Palbociclib.Approved
PalifosfamideAcetyldigitoxin may decrease the cardiotoxic activities of Palifosfamide.Investigational
PamidronateAcetyldigitoxin may decrease the cardiotoxic activities of Pamidronate.Approved
PancuroniumPancuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
PanitumumabAcetyldigitoxin may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatAcetyldigitoxin may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Acetyldigitoxin.Approved, Investigational
ParicalcitolParicalcitol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved, Investigational
ParomomycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Paromomycin.Approved, Investigational
PARP inhibitorAcetyldigitoxin may decrease the cardiotoxic activities of PARP inhibitor.Investigational
PazopanibAcetyldigitoxin may decrease the cardiotoxic activities of Pazopanib.Approved
PazufloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseAcetyldigitoxin may decrease the cardiotoxic activities of Pegaspargase.Approved, Investigational
PembrolizumabAcetyldigitoxin may decrease the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedAcetyldigitoxin may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenbutololPenbutolol may increase the bradycardic activities of Acetyldigitoxin.Approved, Investigational
PenclomedineAcetyldigitoxin may decrease the cardiotoxic activities of Penclomedine.Investigational
PentostatinAcetyldigitoxin may decrease the cardiotoxic activities of Pentostatin.Approved, Investigational
PertuzumabAcetyldigitoxin may decrease the cardiotoxic activities of Pertuzumab.Approved
Phenylacetic acidAcetyldigitoxin may decrease the cardiotoxic activities of Phenylacetic acid.Approved
PindololPindolol may increase the bradycardic activities of Acetyldigitoxin.Approved
PipecuroniumPipecuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
PipobromanAcetyldigitoxin may decrease the cardiotoxic activities of Pipobroman.Approved
PirarubicinAcetyldigitoxin may decrease the cardiotoxic activities of Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Acetyldigitoxin.Experimental
PirfenidoneAcetyldigitoxin may decrease the cardiotoxic activities of Pirfenidone.Investigational
PirlindoleAcetyldigitoxin may decrease the cardiotoxic activities of Pirlindole.Approved
PixantroneAcetyldigitoxin may decrease the cardiotoxic activities of Pixantrone.Investigational
PlevitrexedAcetyldigitoxin may decrease the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinAcetyldigitoxin may decrease the cardiotoxic activities of Plicamycin.Approved, Withdrawn
PodofiloxAcetyldigitoxin may decrease the cardiotoxic activities of Podofilox.Approved
PodophyllinAcetyldigitoxin may decrease the cardiotoxic activities of Podophyllin.Approved
polyacrylic acidAcetyldigitoxin may decrease the cardiotoxic activities of polyacrylic acid.Investigational
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Acetyldigitoxin.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Acetyldigitoxin.Approved
PomalidomideAcetyldigitoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
PonatinibAcetyldigitoxin may decrease the cardiotoxic activities of Ponatinib.Approved
PorfimerAcetyldigitoxin may decrease the cardiotoxic activities of Porfimer.Approved, Investigational
porfiromycinAcetyldigitoxin may decrease the cardiotoxic activities of porfiromycin.Investigational
PractololPractolol may increase the bradycardic activities of Acetyldigitoxin.Approved
PralatrexateAcetyldigitoxin may decrease the cardiotoxic activities of Pralatrexate.Approved
PrednimustineAcetyldigitoxin may decrease the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneAcetyldigitoxin may decrease the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneAcetyldigitoxin may decrease the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Acetyldigitoxin can be increased when it is combined with Primaquine.Approved
ProcarbazineAcetyldigitoxin may decrease the cardiotoxic activities of Procarbazine.Approved
PropafenoneThe serum concentration of Acetyldigitoxin can be increased when it is combined with Propafenone.Approved
PropranololPropranolol may increase the bradycardic activities of Acetyldigitoxin.Approved, Investigational
PropylthiouracilThe serum concentration of Acetyldigitoxin can be increased when it is combined with Propylthiouracil.Approved
Purine RibosideAcetyldigitoxin may decrease the cardiotoxic activities of Purine Riboside.Experimental
PuromycinAcetyldigitoxin may decrease the cardiotoxic activities of Puromycin.Experimental
PyrantelPyrantel may increase the arrhythmogenic activities of Acetyldigitoxin.Approved, Vet Approved
PyrazoloacridineAcetyldigitoxin may decrease the cardiotoxic activities of Pyrazoloacridine.Investigational
Qlt091001Acetyldigitoxin may decrease the cardiotoxic activities of Qlt091001.Investigational
QuinacrineAcetyldigitoxin may decrease the cardiotoxic activities of Quinacrine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Acetyldigitoxin.Approved
QuinidineThe serum concentration of Acetyldigitoxin can be increased when it is combined with Quinidine.Approved
Radium Ra 223 DichlorideAcetyldigitoxin may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedAcetyldigitoxin may decrease the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamucirumabAcetyldigitoxin may decrease the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabAcetyldigitoxin may decrease the cardiotoxic activities of Ranibizumab.Approved
RanpirnaseAcetyldigitoxin may decrease the cardiotoxic activities of Ranpirnase.Investigational
RapacuroniumRapacuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Withdrawn
RegorafenibAcetyldigitoxin may decrease the cardiotoxic activities of Regorafenib.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Acetyldigitoxin.Approved
ResveratrolAcetyldigitoxin may decrease the cardiotoxic activities of Resveratrol.Experimental, Investigational
Rhodamine 6GAcetyldigitoxin may decrease the cardiotoxic activities of Rhodamine 6G.Experimental
RibostamycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Ribostamycin.Approved
RituximabAcetyldigitoxin may decrease the cardiotoxic activities of Rituximab.Approved
RocuroniumRocuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
RomidepsinAcetyldigitoxin may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
RomiplostimAcetyldigitoxin may decrease the cardiotoxic activities of Romiplostim.Approved
RoquinimexAcetyldigitoxin may decrease the cardiotoxic activities of Roquinimex.Investigational
RubitecanAcetyldigitoxin may decrease the cardiotoxic activities of Rubitecan.Investigational
RucaparibAcetyldigitoxin may decrease the cardiotoxic activities of Rucaparib.Investigational
RuxolitinibAcetyldigitoxin may decrease the cardiotoxic activities of Ruxolitinib.Approved
SalirasibAcetyldigitoxin may decrease the cardiotoxic activities of Salirasib.Investigational
SaracatinibAcetyldigitoxin may decrease the cardiotoxic activities of Saracatinib.Investigational
SatraplatinAcetyldigitoxin may decrease the cardiotoxic activities of Satraplatin.Investigational
SeliciclibAcetyldigitoxin may decrease the cardiotoxic activities of Seliciclib.Investigational
SemaxanibAcetyldigitoxin may decrease the cardiotoxic activities of Semaxanib.Investigational
SeocalcitolAcetyldigitoxin may decrease the cardiotoxic activities of Seocalcitol.Experimental
SiltuximabAcetyldigitoxin may decrease the cardiotoxic activities of Siltuximab.Approved
SirolimusAcetyldigitoxin may decrease the cardiotoxic activities of Sirolimus.Approved, Investigational
SisomicinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Sisomicin.Investigational
Sodium phenylbutyrateAcetyldigitoxin may decrease the cardiotoxic activities of Sodium phenylbutyrate.Approved
SolithromycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Solithromycin.Investigational
SonidegibAcetyldigitoxin may decrease the cardiotoxic activities of Sonidegib.Approved, Investigational
SonifilanAcetyldigitoxin may decrease the cardiotoxic activities of Sonifilan.Investigational
SorafenibAcetyldigitoxin may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
SotalolSotalol may increase the bradycardic activities of Acetyldigitoxin.Approved
SP1049CThe serum concentration of Acetyldigitoxin can be decreased when it is combined with SP1049C.Investigational
SparfloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Sparfloxacin.Approved
Sparfosic acidAcetyldigitoxin may decrease the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinAcetyldigitoxin may decrease the cardiotoxic activities of Sparsomycin.Experimental
SpectinomycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Spectinomycin.Approved, Vet Approved
SpiramycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Spironolactone.Approved
squalamineAcetyldigitoxin may decrease the cardiotoxic activities of squalamine.Investigational
SRT501Acetyldigitoxin may decrease the cardiotoxic activities of SRT501.Investigational
StreptomycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Streptomycin.Approved, Vet Approved
StreptozocinAcetyldigitoxin may decrease the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
SulfasalazineThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Sulfasalazine.Approved
SulforaphaneAcetyldigitoxin may decrease the cardiotoxic activities of Sulforaphane.Investigational
SulindacAcetyldigitoxin may decrease the cardiotoxic activities of Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Acetyldigitoxin.Approved
SunitinibAcetyldigitoxin may decrease the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminAcetyldigitoxin may decrease the cardiotoxic activities of Suramin.Approved
SwainsonineAcetyldigitoxin may decrease the cardiotoxic activities of Swainsonine.Experimental
TalaporfinAcetyldigitoxin may decrease the cardiotoxic activities of Talaporfin.Investigational
TamoxifenAcetyldigitoxin may decrease the cardiotoxic activities of Tamoxifen.Approved
TegafurAcetyldigitoxin may decrease the cardiotoxic activities of Tegafur.Approved
TelithromycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Acetyldigitoxin can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Temafloxacin.Withdrawn
TemoporfinAcetyldigitoxin may decrease the cardiotoxic activities of Temoporfin.Approved
TemozolomideAcetyldigitoxin may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusAcetyldigitoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
TeniposideAcetyldigitoxin may decrease the cardiotoxic activities of Teniposide.Approved
TestolactoneAcetyldigitoxin may decrease the cardiotoxic activities of Testolactone.Approved
TetrathiomolybdateAcetyldigitoxin may decrease the cardiotoxic activities of Tetrathiomolybdate.Investigational
TezacitabineAcetyldigitoxin may decrease the cardiotoxic activities of Tezacitabine.Investigational
ThalidomideAcetyldigitoxin may decrease the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiotepaAcetyldigitoxin may decrease the cardiotoxic activities of Thiotepa.Approved
ThymalfasinAcetyldigitoxin may decrease the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiboloneAcetyldigitoxin may decrease the cardiotoxic activities of Tibolone.Approved
TimololTimolol may increase the bradycardic activities of Acetyldigitoxin.Approved
TioguanineAcetyldigitoxin may decrease the cardiotoxic activities of Tioguanine.Approved
TipifarnibAcetyldigitoxin may decrease the cardiotoxic activities of Tipifarnib.Investigational
TirapazamineAcetyldigitoxin may decrease the cardiotoxic activities of Tirapazamine.Investigational
TivozanibAcetyldigitoxin may decrease the cardiotoxic activities of Tivozanib.Investigational
Tnp 470Acetyldigitoxin may decrease the cardiotoxic activities of Tnp 470.Investigational
TobramycinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Tobramycin.Approved, Investigational
TopotecanAcetyldigitoxin may decrease the cardiotoxic activities of Topotecan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Acetyldigitoxin.Approved
ToremifeneAcetyldigitoxin may decrease the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabAcetyldigitoxin may decrease the cardiotoxic activities of Tositumomab.Approved
TrabectedinAcetyldigitoxin may decrease the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibAcetyldigitoxin may decrease the cardiotoxic activities of Trametinib.Approved
TrastuzumabAcetyldigitoxin may decrease the cardiotoxic activities of Trastuzumab.Approved, Investigational
Trastuzumab emtansineAcetyldigitoxin may decrease the cardiotoxic activities of Trastuzumab emtansine.Approved
TreosulfanAcetyldigitoxin may decrease the cardiotoxic activities of Treosulfan.Investigational
TretazicarAcetyldigitoxin may decrease the cardiotoxic activities of Tretazicar.Investigational
TretinoinAcetyldigitoxin may decrease the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Triamterene.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Acetyldigitoxin.Approved, Vet Approved
TrifluridineAcetyldigitoxin may decrease the cardiotoxic activities of Trifluridine.Approved
TrilostaneAcetyldigitoxin may decrease the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimetrexateAcetyldigitoxin may decrease the cardiotoxic activities of Trimetrexate.Approved, Investigational
TriptorelinAcetyldigitoxin may decrease the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideAcetyldigitoxin may decrease the cardiotoxic activities of Trofosfamide.Investigational
TroleandomycinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinAcetyldigitoxin may decrease the cardiotoxic activities of Trovafloxacin.Approved, Withdrawn
TroxacitabineAcetyldigitoxin may decrease the cardiotoxic activities of Troxacitabine.Investigational
TTNPBAcetyldigitoxin may decrease the cardiotoxic activities of TTNPB.Experimental
TubercidinAcetyldigitoxin may decrease the cardiotoxic activities of Tubercidin.Experimental
TubocurarineTubocurarine may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
TylosinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Tylosin.Vet Approved
UbenimexAcetyldigitoxin may decrease the cardiotoxic activities of Ubenimex.Experimental
Uracil mustardAcetyldigitoxin may decrease the cardiotoxic activities of Uracil mustard.Approved
VadimezanAcetyldigitoxin may decrease the cardiotoxic activities of Vadimezan.Investigational
Val 083Acetyldigitoxin may decrease the cardiotoxic activities of Val 083.Investigational
ValrubicinAcetyldigitoxin may decrease the cardiotoxic activities of Valrubicin.Approved
VandetanibAcetyldigitoxin may decrease the cardiotoxic activities of Vandetanib.Approved
VapreotideAcetyldigitoxin may decrease the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
VeliparibAcetyldigitoxin may decrease the cardiotoxic activities of Veliparib.Investigational
VemurafenibAcetyldigitoxin may decrease the cardiotoxic activities of Vemurafenib.Approved
VerapamilVerapamil may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.Approved
VerteporfinAcetyldigitoxin may decrease the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneAcetyldigitoxin may decrease the cardiotoxic activities of Vesnarinone.Investigational
VinblastineAcetyldigitoxin may decrease the cardiotoxic activities of Vinblastine.Approved
VincristineAcetyldigitoxin may decrease the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineAcetyldigitoxin may decrease the cardiotoxic activities of Vindesine.Approved
VinflunineAcetyldigitoxin may decrease the cardiotoxic activities of Vinflunine.Approved
VinorelbineAcetyldigitoxin may decrease the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideAcetyldigitoxin may decrease the cardiotoxic activities of Vintafolide.Investigational
VismodegibAcetyldigitoxin may decrease the cardiotoxic activities of Vismodegib.Approved
Vitamin AAcetyldigitoxin may decrease the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VorinostatAcetyldigitoxin may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
ZorubicinAcetyldigitoxin may decrease the cardiotoxic activities of Zorubicin.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC01AA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9781
Blood Brain Barrier+0.6297
Caco-2 permeable-0.8308
P-glycoprotein substrateSubstrate0.833
P-glycoprotein inhibitor IInhibitor0.7038
P-glycoprotein inhibitor IIInhibitor0.7664
Renal organic cation transporterNon-inhibitor0.8236
CYP450 2C9 substrateNon-substrate0.8663
CYP450 2D6 substrateNon-substrate0.9191
CYP450 3A4 substrateSubstrate0.7356
CYP450 1A2 substrateNon-inhibitor0.9105
CYP450 2C9 inhibitorNon-inhibitor0.9065
CYP450 2D6 inhibitorNon-inhibitor0.9544
CYP450 2C19 inhibitorNon-inhibitor0.9516
CYP450 3A4 inhibitorNon-inhibitor0.8311
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9302
Ames testNon AMES toxic0.9072
CarcinogenicityNon-carcinogens0.9603
BiodegradationNot ready biodegradable0.9769
Rat acute toxicity4.6091 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9794
hERG inhibition (predictor II)Inhibitor0.6255
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility0.0274 mg/L at 25 °CMEYLAN,WM et al. (1996)
logP3.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0123 mg/mLALOGPS
logP2.87ALOGPS
logP4.04ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)7.18ChemAxon
pKa (Strongest Basic)0.24ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area188.9 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity200.87 m3·mol-1ChemAxon
Polarizability87.95 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentCardenolide glycosides and derivatives
Alternative Parents
Substituents
  • Cardanolide-glycoside
  • Steroidal glycoside
  • Oligosaccharide
  • Hydroxysteroid
  • Oxane
  • 2-furanone
  • Acetate salt
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tertiary alcohol
  • Dihydrofuran
  • Cyclic alcohol
  • Secondary alcohol
  • Lactone
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Gonzalez-Garcia C, Cena V, Klein DC: Characterization of the alpha +-like Na+,K+-ATPase which mediates ouabain inhibition of adrenergic induction of N-acetyltransferase (EC 2.3.1.87) activity: studies with isolated pinealocytes. Mol Pharmacol. 1987 Dec;32(6):792-7. [PubMed:2826993 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23